National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

Cancerforskningsfondet Af 1989

Other

University of Pittsburgh

Government of the United States

The United States of America As Represented by the Secretary, Department

Ettore Appella

Teizo Yoshimura

Edward J Leonard

Kouji Matsushima

Stephen D Showalter

Elizabeth A Robinson

John K Inman

Joost Oppenheim

William G Rice

Joost J Oppenheim

Vincent Ellis

Mingjun Huang

Eeva-Marjatta Salonen

Atul Goel

Charles Pyke

David Covell

Michael Ploug

James A Turpin

Niels Behrendt

Peter Kristensen

Marco Schito

Ross W Stephens

Antti Vaheri

Hannele Tapiovaara

Ann Louring Roldan

Francesco Blasi

Yongsheng Song

Maria Teresa Masucci

Anders Wallqvist

Maria Vittoria Cubellis

Jim A Turpin

Andrew Maynard

Anne Kallioniemi

Albert J Fornace, Jr

Wolf-Dieter Schleuning

Keld Dano Slashed

Ebbe Ro Slashednne

Keld Dan&oslash;

Wd Schleuning

Jari P&ouml;ll&auml;nen

Dmitry Bulavin

Lisbeth Birk M&oslash;ller

Leif R&oslash;ge Lund

L&aacute;szlo Patthy

Douglas Loftus

Albert B DeLeo

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Jari Pollanen

Ebbe R&oslash;nne

Schito Marco

Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.

Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents

This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thiolester-inactivated viruses and thiolester-complexed viral proteins.

Thiolesters and uses thereof

Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents

Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.

Materials and methods for inhibiting Wip1

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof

An isolated cDNA molecule comprising an amino acid sequence encoding an amino-terminal protein fragment of murine glycoprotein 110 is disclosed. Therapeutic methods for treating tumor-bearing patients are also disclosed, as are prophylactic methods for vaccinating patients. An animal model for studying tumors is also disclosed.

cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Nucleic acids encoding a novel neutrophil chemotactic factor

Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.

Urokinase-type plasminogen activator receptor

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.

Human derived monocyte attracting purified peptide products useful in a

An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Method of treating inflammation with antibodies to neutrophil

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a

Growing community of inventors

Chevy Chase, MD, United States of America

Ettore Appella